Elraglusib Doubles Survival Rate in Pancreatic Cancer, Nature Medicine Publishes Pivotal Phase 2 Data
Summary
Actuate Therapeutics announced the publication of its Phase 2 clinical trial results for elraglusib in Nature Medicine, demonstrating a doubling of the one-year survival rate (44.1% vs 22.3%) and a 40% improvement in median overall survival (10.1 months vs 7.2 months) when combined with chemotherapy for previously untreated metastatic pancreatic cancer. The trial also showed a 38% reduction in the risk of death. This highly positive, peer-reviewed data is critical for Actuate, a small biopharmaceutical company with a market capitalization of approximately $43 million, especially given its recent 10-K filing (March 26, 2026) which included a going concern warning and indicated cash would only last until July 2026. The significant clinical benefit in a difficult-to-treat cancer could be a transformative catalyst, potentially facilitating partnerships, further financing, or accelerated regulatory pathways. Investors will closely monitor any developments regarding elraglusib's path forward and the company's ability to secure funding to extend its operational runway.
At the time of this announcement, ACTU was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.2M. The 52-week trading range was $1.58 to $11.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.